Sandoz Valuation Multiples

Sandoz Overview

About Sandoz

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz’s total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe’s first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.

Founded

1996

HQ

Employees

23.6K

Website

sandoz.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $11B

EBITDA: $2B

EV

$41B

Valuation Multiples

Multiples.vc

Start free trial

Sandoz Financials

Sandoz reported last 12-month revenue of $11B and EBITDA of $2B.

In the same LTM period, Sandoz generated $6B in gross profit, $2B in EBITDA, and $1B in net income.

Sandoz P&L

In the most recent fiscal year, Sandoz reported revenue of $11B and EBITDA of $2B.

Sandoz expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sandoz Stock Performance

Sandoz has current market cap of $37B, and enterprise value of $41B.

Sandoz's stock price is $85.75.

Sandoz Valuation Multiples

Sandoz trades at 3.6x EV/Revenue multiple, and 16.5x EV/EBITDA.

Sandoz Financial Valuation Multiples

As of April 18, 2026, Sandoz has market cap of $37B and EV of $41B.

Equity research analysts estimate Sandoz's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sandoz has a P/E ratio of 35.0x.

Sandoz Margins & Growth Rates

Sandoz's revenue in the last 12 month grew by 8%.

Sandoz's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Sandoz's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sandoz's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sandoz Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sandoz M&A Activity

Sandoz acquired XXX companies to date.

Last acquisition by Sandoz was on XXXXXXXX, XXXXX. Sandoz acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sandoz Investment Activity

Sandoz invested in XXX companies to date.

Sandoz made its latest investment on XXXXXXXX, XXXXX. Sandoz invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).